Biologics by McKesson and Onco360 Selected as Specialty Pharmacy Partners for Fruzaqla, Ogsiveo, and Truqap

Takeda – Fruzaqla™ is an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type (WT) and medically appropriate, an anti-EGFR therapy. Fruzaqla™ is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status. Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.

SpringWorks Therapeutics – Ogsiveo^™ (nirogacestat) is an oral gamma secretase inhibitor for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.

AstraZeneca – Truqap^™ (capivasertib) is an oral targeted therapy for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation.

Founded in 1994, Biologics by McKesson is an independent specialty pharmacy committed to connecting patients to life-changing medications in oncology and other complex and rare diseases. Built on the foundation of deep clinical expertise and a white-glove approach to patient care, Biologics delivers both patients and partners seamless access to therapies and unmatched personalized engagement, so its patients get the most out of the care they receive.

The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends.